An organ-preserving approach to muscle-invading transitional cell cancer of the bladder

Hematology/Oncology Clinics of North America

Volumn 15, Issue 2, 2001, Pages 345-358

  Brown Jr, Alan L ^b   Zietman, Anthony L ^b   Shipley, William U ^b   Kaufman, Donald S ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CYSTECTOMY; HUMAN; MULTIMODALITY CANCER THERAPY; ORGAN PRESERVATION; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0035033542     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70216-1     Document Type: Article

References (63)

1. Cisplatin and radiation interaction probabilities and therapeutic possibilities
2. Local recurrence and survival following nerve-sparing radical cystoprostatectomy
3. Combined chemotherapy and radiotherapy in muscle-invasive bladder carcinoma: Complete remission results
4. Radiotherapy for T2 and T3 carcinoma of the bladder: The influence of overall treatment time
5. A organ-sparing treatment of advanced bladder cancer: A 10-year experience
6. Response of cell populations in spheroids to radiation-drug combinations
7. Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report)
8. Additive effects of cisplatin and radiation in humor tumor cells under toxic conditions
9. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, methotrexate and vinblastine chemotherapy for muscle invasive bladder cancer
10. Local control after cystectomy alone in bladder carcinoma
11. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: A meta-analysis of individual patient data from randomized clinical trials
12. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis
13. The place of radiation therapy as definitive treatment of bladder cancer
14. Cancer statistics, 2000
15. Neoadjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer: First analysis of MRC/EORTC intercontinental trial
16. Transurethral resection for transitional cell carcinoma
17. Neoadjuvant chemotherapy, a method to conserve the bladder
18. Treatment of invasive bladder cancer by local resection and high dose methotrexate
19. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, or cutaneous or urethral Kock pouch
20. Comparison of transurethral resection to radical therapies for stage B bladder tumors
21. Conservative management of muscle-infiltrating bladder cancer: Prospective experience
22. Organ conservation in bladder cancer
23. Concomitant 5-fluorouracil-cisplatin and bifractionated split course radiation therapy for invasive bladder cancer
24. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study
25. Systemic therapy for invasive bladder cancer
26. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive bladder cancer
27. Bladder preservation in invasive locally confined bladder cancer
28. Bladder preservation by combined modality therapy in invasive bladder cancer
29. Combined modality treatment with bladder conservation for invasive bladder cancer: Long-term tolerance in the female patient
30. Extended experience with neoadjuvant M-VAC chemotherapy for invasive transitional cell carcinoma of the urinary bladder
31. Transitional cell carcinoma of the bladder: A phase II study of chemotherapy in T3-4 N0 M0 of the EORTC GU group
32. Sexual function following radical radiotherapy for bladder cancer
33. The quality of life after radical radiotherapy for bladder cancer
34. Systemic preoperative chemotherapy with cisplatin, methotrexate, and vinblastine for locally advanced bladder cancer: Local tumor response and early follow-up results
35. Five-year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1
36. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder
37. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study
38. Continent urinary diversion
39. Bladder cancer: Superiority of preoperative radiation in cystectomy in clinical stage T3
40. Bladder cancer
41. Results of contemporary radical cystectomy for invasive bladder cancer: A clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification
42. Bladder cancer
43. Invasive transitional cell carcinoma of the bladder: Prognosis and management
44. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy
45. Primary radical radiotherapy for T3 transitional cell cancer of the bladder: An analysis of survival and control
46. Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder
47. Efficacy of radiochemotherapy with platinum derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer
48. Neoadjuvant chemotherapy for invasive bladder cancer: Experience with the MVAC regimen
49. Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival in patients treated with MVAC with 5-year follow-up
50. Treatment of advanced bladder cancer category T2, T3, T4a
51. Adjuvant chemotherapy in T3 carcinoma of the bladder
52. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy
53. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of RTOG 89-03
54. Invasive bladder cancer: Treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation
55. The role of adjuvant chemotherapy following cystectomy for Invasive bladder cancer: A prospective comparative trial
56. Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patient
57. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study
58. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12
59. Neoadjuvant combined modality therapy with possible organ preservation for invasive bladder cancer
60. Neoadjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder
61. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer
62. The combination of cis-platinum based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder